Early research (Phase 1)Study completedNCT02996461
What this trial is testing
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults
Who this might be right for
Prevention of Zika InfectionZika-Specific Immune Response
National Institute of Allergy and Infectious Diseases (NIAID) 45